Dexcom (DXCM) Amortization of Deferred Charges (2010 - 2026)

Dexcom (DXCM) has 12 years of Amortization of Deferred Charges data on file, last reported at $1.0 million in Q1 2026.

• Amortization of Deferred Charges for Q1 2026 came in at $1.0 million, down 47.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.4 million (down 14.67% YoY), and the FY2025 annual result was $7.3 million, down 2.67% from the prior year.
• Amortization of Deferred Charges eased to $1.0 million in Q1 2026 per DXCM's latest filing, from $1.7 million in the prior quarter.
• Over five years, Amortization of Deferred Charges peaked at $2.2 million in Q3 2023 and troughed at $1.0 million in Q1 2026.
• A 5-year average of $1.8 million and a median of $1.8 million in 2024 frame the typical range for Amortization of Deferred Charges.
• The sharpest annual moves came in 2023 and 2026: Amortization of Deferred Charges surged 46.67% in 2023, then tumbled 47.37% in 2026.
• A 5-year view of Amortization of Deferred Charges shows it stood at $1.6 million in 2022, then advanced by 25.0% to $2.0 million in 2023, then declined by 5.0% to $1.9 million in 2024, then decreased by 10.53% to $1.7 million in 2025, then plunged by 41.18% to $1.0 million in 2026.
• Business Quant data shows DXCM's Amortization of Deferred Charges at $1.0 million in Q1 2026, $1.7 million in Q4 2025, and $1.9 million in Q3 2025.